As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive, high-yield corridors of the healthcare sector. At the center of this movement is Gilead Sciences (Nasdaq: GILD), which has defied its decade-long
As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying technology giants, investors have executed a massive "Great Rotation," fleeing overextended tech valuations in favor of the stability and renewed
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the Delaware-based biopharmaceutical giant is currently undergoing a radical transformation. Today, the stock is under heavy scrutiny following yesterday’s fiscal year 2025 earnings report. While [...]
AbbVie’s fourth quarter results came in above Wall Street’s revenue and profit expectations, but the market responded negatively, reflecting concerns over certain business segments and future headwinds. Management attributed the quarter’s performance to robust growth in its immunology and neuroscience franchises, especially from SKYRIZI, RINVOQ, and Vraylar. Meanwhile, ongoing declines in HUMIRA due to biosimilar competition and continued softness in the aesthetics segment tempered overall results. CEO Robert Michael highlighted the company’s ability to offset HUMIRA erosion with strong execution in other therapeutic areas and a diversified portfolio.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital,
and those that can maintain this trifecta year in and year out often become the legends of the investing world.
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a record-shattering $240 billion in total M&A investment in 2025, represents a fundamental shift in how
Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 6% year on year to $16 billion. Its non-GAAP profit of $2.71 per share was 2.2% above analysts’ consensus estimates.
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10% year on year to $16.62 billion. Its non-GAAP profit of $2.71 per share was 2.2% above analysts’ consensus estimates.
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative fervor surrounding a potential multi-billion-dollar acquisition of the company began to dissolve, leaving investors to grapple with a "news
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.
